Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

2026 Issues

Pathology informatics selected abstracts

July 2026—Apollo is a health care-scale multimodal foundation model designed to integrate longitudinal clinical data into unified virtual patient representations. It was developed by the authors using data from a major U.S. health care system and trained on approximately 25 billion clinical records from 7.2 million patients that spanned more than three decades. The data set incorporated 12 medical specialties and 28 clinical modalities, including pathology images, laboratory testing, clinical documentation, medications, and structured electronic health record data.

Q&A column

July 2026
Q. What is the recommended approach for determining the HIV status of patients who are taking HIV pre-exposure prophylaxis or have received oral PrEP within the past three months or intramuscular PrEP within the past 12 months? Read answer.
Q. Our providers pointed out that lipoprotein(a) results from different laboratories are discordant, so they asked us to bring the assay in-house. Is this a good idea? Read answer.

Newsbytes

July 2026—Dedicated training in histology is increasingly getting short shrift as many academic medical institutions nationwide move to an organ system-based teaching structure. Recognizing this trend, a group of faculty and residents at the University of Wisconsin School of Medicine and Public Health are employing creativity, a simple software program, and a bit of teamwork to boost medical students’ exposure to the specialty.

Letters

July 2026—The volume of information pathology residents need to know by the end of residency to pass the board exams is extraordinarily large. Certain subspecialties within pathology such as hematopathology can be especially challenging because there are hundreds of CD markers, which can make memorizing them and their associated diseases difficult. Articles have been published on the overload and stress pathology trainees feel.

Put It on the Board

July 2026—The renewed restriction on remote participation in cytology workflows could have unintended consequences for access to and efficiency and continuity of care, write authors of a Correspondence published online in May in Nature Medicine.

Early days for menin inhibitor monitoring

June 2026—In the cat-and-mouse maneuverings that often propel new cancer treatments, menin inhibitors are proving to be successful epigenetic therapies for acute leukemia. Last November brought FDA approval of revumenib for treatment of adults and children (one year and older) with relapsed or refractory acute myeloid leukemia with NPM1 gene mutations.

IHC workup of lung neuroendocrine neoplasms

June 2026—The immunostaining landscape for lung neuroendocrine tumors continues to evolve, and Humberto Trejo Bittar, MD, in a CAP25 lung cancer session last fall, captured where it stands.

Lab leaders weigh alternative revenue models

June 2026—Alternative revenue models for laboratories, specifically laboratory testing for functional health and other health care practices that traditionally haven’t been part of conventional medicine, came up in a May 6 online Compass Group roundtable, led by CAP TODAY publisher Bob McGonnagle.

Health insurer consolidation: a case of the tail wagging the dog

June 2026—The primary reason for health insurance is to help patients pay for medical care when they need it. Beneficiaries pay their premiums when healthy to receive payouts when sick. Sounds simple, and at its inception it was. Dallas, Tex., gave birth in 1929 to the precursor of the Blue Cross system. Plan members paid in, and if hospitalization was needed, care was rendered and fees were paid by the community pool. But we’ve come a long way since then.

MARKETPLACE

TRENDING